Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration

Respiratory Research - Tập 8 - Trang 1-11 - 2007
Reinhold Schmidt1, Philipp Markart1, Clemens Ruppert1, Malgorzata Wygrecka1, Tim Kuchenbuch1, Dieter Walmrath1, Werner Seeger1, Andreas Guenther1
1University of Giessen Lung Center (UGLC), Medical Clinic II, Giessen, Germany

Tóm tắt

Alterations to pulmonary surfactant composition have been encountered in the Acute Respiratory Distress Syndrome (ARDS). However, only few data are available regarding the time-course and duration of surfactant changes in ARDS patients, although this information may largely influence the optimum design of clinical trials addressing surfactant replacement therapy. We therefore examined the time-course of surfactant changes in 15 patients with direct ARDS (pneumonia, aspiration) over the first 8 days after onset of mechanical ventilation. Three consecutive bronchoalveolar lavages (BAL) were performed shortly after intubation (T0), and four days (T1) and eight days (T2) after intubation. Fifteen healthy volunteers served as controls. Phospholipid-to-protein ratio in BAL fluids, phospholipid class profiles, phosphatidylcholine (PC) molecular species, surfactant proteins (SP)-A, -B, -C, -D, and relative content and surface tension properties of large surfactant aggregates (LA) were assessed. At T0, a severe and highly significant reduction in SP-A, SP-B and SP-C, the LA fraction, PC and phosphatidylglycerol (PG) percentages, and dipalmitoylation of PC (DPPC) was encountered. Surface activity of the LA fraction was greatly impaired. Over time, significant improvements were encountered especially in view of LA content, DPPC, PG and SP-A, but minimum surface tension of LA was not fully restored (15 mN/m at T2). A highly significant correlation was observed between PaO2/FiO2 and minimum surface tension (r = -0.83; p < 0.001), SP-C (r = 0.64; p < 0.001), and DPPC (r = 0.59; p = 0.003). Outcome analysis revealed that non-survivors had even more unfavourable surfactant properties as compared to survivors. We concluded that a profound impairment of pulmonary surfactant composition and function occurs in the very early stage of the disease and only gradually resolves over time. These observations may explain why former surfactant replacement studies with a short treatment duration failed to improve outcome and may help to establish optimal composition and duration of surfactant administration in future surfactant replacement studies in acute lung injury.

Tài liệu tham khảo

Hawgood S, Clements JA: Pulmonary surfactant and its apoproteins. J Clin Invest 1990, 86:1–6. Veldhuizen R, Nag K, Orgeig S, Possmayer F: The role of lipids in pulmonary surfactant. Biochim Biophys Acta 1998, 1408:90–108. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L: Evidence of lung surfactant abnormality in respiratory failure. J Clin Invest 1982, 70:673–683. Pison U, Seeger W, Buchhorn R, Joka T, Brand M, Obertacke U, Neuhof H, Schmit-Neuerburg KP: Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989, 140:1033–1039. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA III, Hudson LD, Maunder RJ, Crim C, Hyers TM: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991, 88:1976–1981. Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W: Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996, 153:176–184. Schmidt R, Steinhilber W, Ruppert C, Daum C, Grimminger F, Seeger W, Günther A: An ELISA technique for quantification of surfactant apoprotein (SP)-C in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 2002, 165:470–474. Schmidt R, Meier U, Yabut-Perez M, Walmrath D, Grimminger F, Seeger W, Günther A: Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome (ARDS) and severe pneumonia. Am J Respir Crit Care Med 2001, 163:95–100. Seeger W, Guenther A, Thede C: Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 1992, 262:L286-L291. Seeger W, Grube C, Günther A, Schmidt R: Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993, 6:971–977. Ruppert C, Pucker C, Markart P, Schmidt R, Grimminger F, Seeger W, Stürzebecher J, Günther A: Selective inhibition of large-to-small surfactant aggregate conversion by serine protease inhibitors of the bis-benzamidine type. Am J Respir Cell Mol Biol 2003, 28:95–102. Holm BA, Keicher L, Liu MY, Sokolowski J, Enhorning G: Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 1991, 71:317–321. Putman E, van Golde LM, Haagsman HP: Toxic oxidant species and their impact on the pulmonary surfactant system. Lung 1997, 175:75–103. Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 342:1301–1308. Tasaka S, Hasegawa N, Ishizaka A: Pharmacology of acute lung injury. Pulm Pharmacol Ther 2002, 15:83–95. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA, the Pediatric Acute Lung Injury and Sepsis Investigators: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005, 293:470–476. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F, Hafner D, Taut FJ, Seeger W: Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004, 351:884–892. Walmrath D, Grimminger F, Pappert D, Knothe C, Obertacke U, Benzing A, Gunther A, Schmehl T, Leuchte H, Seeger W: Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J 2002, 19:805–810. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai GZ, Hite RD, Smith RM, Hudson LD, Crim C, Newton P, Mitchell BR, Gold AJ: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997, 155:1309–1315. Walmrath D, Günther A, Ghofrani HA, Schermuly R, Schneider T, Grimminger F, Seeger W: Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996, 154:57–62. Guenther A, Schmidt R, Harodt J, Schmehl T, Walmrath D, Ruppert C, Grimminger F, Seeger W: Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J 2002, 19:797–804. Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, Marsh JJ: Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003, 167:1562–1566. Nakos G, Tsangaris H, Liokatis S, Kitsiouli E, Lekka ME: Ventilator-associated pneumonia and atelectasis: evaluation through bronchoalveolar lavage fluid analysis. Intensive Care Med 2003, 29:555–563. Greene KE, Wright JR, Steinberg KP, Ruszinski JT, Caldwell E, Wong WB, Hull W, Whitsett JA, Akino T, Kuroki Y, Nagae H, Hudson LD, Martin TR: Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999, 160:1843–1850. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The american-european consensus conference on ARDS. Am J Respir Crit Care Med 1994, 149:818–824. Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier JM, Beaucaire G: A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995, 21:24–31. Lohmeyer J, Friedrich J, Grimminger F, Maus U, Tenter R, Morr H, Velcovsky HG, Seeger W, Rosseau S: Expression of mucosa-related integrin alphaEbeta7 on alveolar T cells in interstitial lung diseases. Clin Exp Immunol 1999, 116:340–346. Ruestow B, Schlame M, Haupt R, Wilhelm D, Kunze D: Studies on the formation of dipalmitoyl species of phosphatidylcholine and phosphatidylethanolamine in pulmonary type II cells. Biochem J 1992, 282:453–458. Krämer HJ, Schmidt R, Günther A, Becker G, Suzuki Y, Seeger W: ELISA technique for quantification of surfactant protein B (SP-B) in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 1995, 152:1540–1544. Griese M, Maderlechner N, Ahrens P, Kitz R: Surfactant proteins A and D in children with pulmonary disease due to gastroesophageal reflux. Am J Respir Crit Care Med 2002, 165:1546–1550. Veldhuizen R, Inchley K, Hearn SA, Lewis JF, Possmayer F: Degradation of surfactant-associated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates. Biochem J 1993, 295:141–147. Enhorning G: Pulsating bubble technique for evaluating pulmonary surfactant. J Appl Physiol 1977, 43:198–203. Pelosi P, Caironi P, Gattinoni L: Pulmonary and extrapulmonary forms of acute respiratory distress syndrome. Semin Respir Crit Care Med 2001, 22:259–268. Moran JL, Solomon PJ, Fox V, Salagaras M, Williams PJ, Quinlan K, Bersten AD: Modelling thirty-day mortality in the Acute Respiratory Distress Syndrome (ARDS) in an adult ICU. Anaesth Intensive Care 2004, 32:317–329. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000, 342:1334–1349. Pison U, Obertacke U, Brand M, Seeger W, Joka T, Bruch J, Schmit-Neuerburg KP: Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma 1990, 30:19–26. Nakos G, Kitsiouli EI, Tsangaris I, Lekka ME: Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components. Intensive Care Med 1998, 24:296–303. Shelley SA, Balis JU, Paciga JE, Espinoza CG, Richman AV: Biochemical composition of adult human lung surfactant. Lung 1982, 160:195–206. Post M, Schuurmans EA, Batenburg JJ, Van Golde LM: Mechanisms involved in the synthesis of disaturated phosphatidylcholine by alveolar type II cells isolated from adult rat lung. Biochim Biophys Acta 1983, 750:68–77. Esko JD, Raetz CR: Lipid Enzymology – Phospholipid synthesis in animal cells. In The Enzymes. Volume 16. 3rd edition. Edited by: Boyer PD. New York: Academic Press; 1983:226. Veldhuizen RA, Welk B, Harbottle R, Rearn S, Nag K, Petersen N, Possmayer F: Mechanical ventilation of isolated rat lungs changes the structure and biophysical properties of surfactant. J Appl Physiol 2002, 92:1169–1175. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996, 334:1417–1421.